Catheter-directed thrombolysis with alteplase and bivalirudin in a patient with heparin-induced thrombocytopenia

American Journal of Health-System Pharmacy

Volumn 72, Issue 9, 2015, Pages 707-710

  Martinez, Larissa A ^a   Burnett, Allison E ^a,b  

^a UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ENOXAPARIN; FONDAPARINUX; HIRULOG; ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ABSENCE; ADULT; AORTA INJURY; AORTIC LACERATION; ARTICLE; ASTHMA; BODY MASS; BRAIN EDEMA; CASE REPORT; CATHETER DIRECTED THROMBOLYSIS; CAUCASIAN; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DOPPLER FLOWMETRY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FIBRINOLYSIS; FLUID RESUSCITATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INFERIOR CAVA VEIN; MIDDLE AGED; MORBID OBESITY; OXYGEN SATURATION; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; PLEURA EFFUSION; PRIORITY JOURNAL; RENAL LACERATION; SPINE FRACTURE; SUBDURAL HEMATOMA; TACHYPNEA; THROMBOCYTE COUNT; TRAFFIC ACCIDENT; CATHETERIZATION; CHEMICALLY INDUCED; FIBRINOLYTIC THERAPY; PATHOPHYSIOLOGY; PROCEDURES; THROMBOCYTOPENIA;

ANTICOAGULANTS; CATHETERIZATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HIRUDINS; HUMANS; MIDDLE AGED; OBESITY, MORBID; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84942412465     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp140474     Document Type: Article

References (14)

1. Warkentin T, Levine M, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecularweight heparin or unfractionated heparin. N Engl J Med. 1995; 332:1330-6.
2. Linkins L, Dans AL, Moores LK et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(suppl):e495S-530S.
3. Warkentin T, Sheppard J, Sigouin C et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006; 108:2937-41.
4. Lubenow N, Hinz P, Thomaschewski S et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood. 2010; 115:1797-803.
5. Patterson BO, Hinchliffe R, Loftus IM et al. Indications for catheter-directed thrombolysis in the management of acute proximal deep venous thrombosis. Arterioscler Thromb Vasc Biol. 2010; 30:669-74.
6. Lo GK, Juhl D, Warkentin TE et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4:759-65.
7. Maldonado A. Argatroban and catheterdirected thrombolysis with alteplase for limb- and graft-threatening thromboses in a patient with a history of HIT. Am J Hematol. 2009; 84:251-3.
8. Turba UC, Bozlar U, Simsek S. Catheterdirected thrombolysis of acute lower extremity arterial thrombosis in a patient with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv. 2007; 70:1046-50.
9. Jung M, McCarthy JJ, Baker KR et al. Safety of IVC filters with heparin-induced thrombocytopenia: a retrospective study. Paper presented at American Society of Hematology Annual Meeting and Exposition. San Diego, CA; 2011 Dec 11.
10. Ishibashi H, Takashi O, Hosaka M et al. Heparin-induced thrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement. Int Angiol. 2005; 24:387-90.
11. Warkentin TE, Pai M, Sheppard JI et al. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011; 9:2389-96.
12. Serasli E, Antoniadou M, Tsara V et al. Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series. Thromb J. 2008; 6:9.
13. Nutescu EA, Spinler SA, Wittkowsky A et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009; 43:1064-83.
14. Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res. 2012; 129:407-17.